证券代码：002773 证券简称：康弘药业 成都康弘药业集团股份有限公司投资者关系活动记录表 编号：2018-01 | --- | --- | --- | --- | --- | --- | --- | |----------------|-------------------------------------------------------|-------|---------------|-------|-------|-------| | | | | | | | | | 投资者关系活动 | □ 特定对象调研 □分析师会议 | | | | | | | 类别 | □媒体采访 √业绩说明会 | | | | | | | | □ 新闻发布会 □路演活动 | | | | | | | | □现场参观 | | | | | | | | □ 其他 | | | | | | | 参与单位名称及 | 投资者 | | | | | | | | | | | | | | | 人员姓名 | | | | | | | | 时间 | 2018 年 5 月 8 日 | | | | | | | 地点 | " 全 景 · 为： http://rs ...

证券代码：002773 证券简称：康弘药业 成都康弘药业集团股份有限公司投资者关系活动记录表 编号：2018-07 | --- | --- | --- | |----------------|-----------------------------|--------------------------------------------------| | | | | | 投资者关系活动 | □ | 特定对象调研 □分析师会议 | | 类别 | □媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □现场参观 | | | | √ 其他 上市公司投资者交流会 | | | 参与单位名称及 | | 证券公司、基金公司、资产管理公司等 | | 人员姓名 | | | | 时间 | 2018 年 9 月 17 | 日 11:00-12:00 | | 地点 | 成都市金牛区蜀西路 | 36 号公司四楼会议室。 | | 上市公司接待人 | | | | 员姓名 | | 副总裁、财务总监、董秘：钟建军先生 | | 投资者关系活动 | | 本次投资者交流会对公司基本情况进行了介绍，并与投 | 1 / ...

证券代码：002773 证券简称：康弘药业 编号：2018-05 成都康弘药业集团股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|-----------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | □ | 特定对象调研 □分析师会议 | | 类别 | □媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □现场参观 | | | | √ 其他 上市公司投资者交流会 | | | 参与单位名称及 | | 证券公司、基金公司、资产管理公司等（名单附后，按参加 | | 人员姓名 | | 活动人员所属机构名称拼音首字母排序） | | 时间 | 2018 年 9 月 6 日 | | | 地点 | 成都市金牛区蜀西路 | 36 号公司会议室。 | | 上市公司接待人 | | 副总裁、财务总监、董秘：钟建军先生 | | 员姓名 | 证券事务代表：邓康先生 | | | 投资者关系活动 | | 本 ...

证券代码：002773 证券简称：康弘药业 成都康弘药业集团股份有限公司投资者关系活动记录表 编号：2018-08 | --- | --- | --- | |----------------|-----------------------------|--------------------------------------------------| | | | | | 投资者关系活动 | □ | 特定对象调研 □分析师会议 | | 类别 | □媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □现场参观 | | | | √ 其他 上市公司投资者交流会 | | | 参与单位名称及 | | 证券公司、基金公司、资产管理公司等 | | 人员姓名 | | | | 时间 | 2018 年 9 月 19 | 日 10:30-12:00 | | 地点 | 成都市金牛区蜀西路 | 36 号公司四楼会议室。 | | 上市公司接待人 | | | | 员姓名 | | 副总裁、财务总监、董秘：钟建军先生 | | 投资者关系活动 | | 本次投资者交流会对公司基本情况进行了介绍，并与投 | 1 / ...

Group 1: R&D Progress and Pipeline - The company has a diverse pipeline focusing on small molecule drugs, biologics, gene therapy, and antibody development, with several projects in various stages of development [2][3]. - The small molecule drug KH617 for glioma has applied for PCT patent and is undergoing GLP safety evaluation, with clinical trial applications being prepared for submission in both China and the US [2]. - The KH629 project for treating NASH is progressing normally, and multiple projects utilizing AI technology and special formulations have transitioned from R&D to development stages [3]. Group 2: Clinical Trials and Innovations - The company aims to introduce one original Class 1 new product into clinical trials each year over the next three years [3]. - The antibody project KH906 for treating ocular neovascularization is about to enter Phase II clinical trials, while KH903 for gastric and colorectal cancer is nearing completion of Phase II trials [3]. - The company is developing an AAV delivery system for gene therapy, with products like KH631 showing sustained efficacy in preclinical models and expected to submit clinical trial applications by the end of 2021 or early 2022 [3]. Group 3: Clinical Trial Challenges - The global Phase III clinical trial of Conbercept faced setbacks, with preliminary data analysis ongoing and further investigation required to understand the results [4]. - The company is reconsidering the future plans for its Beijing factory due to the termination of the overseas clinical trial, although the factory is expected to play a significant role in the future of biopharmaceuticals [4]. Group 4: Financial Overview - As of the end of 2020, the company reported cumulative development expenses of 139,692.30 million yuan, which were expensed in the current period [4]. - The company has not yet predicted the expenses related to the halted PANDA trial for 2021 [5].

Group 1: Clinical Trials and Product Development - The clinical trial for Kangbaxipu (康柏西普) faced failures due to various factors, and the company is currently analyzing the data to understand the reasons [2][3][4] - Kangbaxipu has been on the market for 7 years, with cumulative sales exceeding 1 billion CNY for two consecutive years, indicating strong market performance [4][5] - The company is advancing several projects, including KH805 and KH806 for diabetes, which are in preclinical research stages [5][8] Group 2: Financial Performance and Investor Relations - The company's stock price is influenced by its performance and growth potential, with ongoing efforts to meet annual growth targets [3][4] - Kangbaxipu's sales in the first four months of 2021 showed continued growth, reinforcing confidence in achieving financial targets for the year [4][5] - The company has maintained a research and development investment of around 20% in recent years, although this may fluctuate due to the impact of halted overseas trials [6][7] Group 3: Market Strategy and Future Plans - The company does not currently plan to enter the medical aesthetics market, focusing instead on its core pharmaceutical business [7][8] - Future product lines include innovative drugs in various therapeutic areas, with a commitment to developing first-in-class or best-in-class products [8][9] - The company is exploring opportunities in synthetic biology and gene therapy, with several projects progressing well [7][8]

成都康弘药业集团股份有限公司 2022 年第三季度报告 证券代码：002773 证券简称：康弘药业 公告编号：2022-084 成都康弘药业集团股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度报告是否经过审计 □是 否 1 成都康弘药业集团股份有限公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |------------------------------------------------------|------------------|-------------------------|--- ...

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 1,763,392,394.14, a decrease of 7.18% compared to CNY 1,899,864,428.98 in the same period last year[11]. - Net profit attributable to shareholders of the listed company reached CNY 537,087,027.60, an increase of 27.73% from CNY 420,490,245.58 year-on-year[11]. - The net profit after deducting non-recurring gains and losses was CNY 499,955,900.11, reflecting a growth of 29.02% compared to CNY 387,504,239.72 in the previous year[11]. - The net cash flow from operating activities was CNY 442,950,909.11, a significant increase of 244.42% from CNY 128,606,535.97 in the same period last year[11]. - Basic earnings per share were CNY 0.58, up 26.09% from CNY 0.46 in the previous year[11]. - Total assets at the end of the reporting period amounted to CNY 7,312,123,336.81, representing a 5.12% increase from CNY 6,956,079,910.12 at the end of the previous year[11]. - Net assets attributable to shareholders of the listed company were CNY 6,538,937,288.22, an increase of 7.38% from CNY 6,089,760,363.45 at the end of the previous year[11]. - The weighted average return on net assets was 8.47%, up from 7.07% in the previous year, indicating improved profitability[11]. Research and Development - The company has established four key technological platforms to enhance its core competencies in drug development[16]. - The company emphasizes innovation and collaboration as part of its growth strategy, aiming for high-quality and sustainable development[16]. - The company has developed a series of proprietary or exclusive products in the treatment of chronic diseases such as hypertension and diabetes, focusing on high-incidence diseases with significant market potential[19]. - The company has launched new products, including the KH906 eye drops, which are in Phase Ib clinical trials, and KH903, a Class 1 biological new drug in Phase II trials[25]. - Research and development expenses were CNY 132,175,902.11, significantly lower than CNY 445,034,907.63 in the previous year, indicating a decrease of 70.3%[132]. Market Expansion - The company is actively expanding its international presence, having signed an overseas cooperation agreement with IOPtima Ltd. in 2017, which granted it control over IOPtima and exclusive distribution rights for its products in China[21]. - The company plans to expand its market presence in Southeast Asia, targeting a 25% increase in sales from this region by 2023[58]. - The company plans to launch three new products in the next quarter, targeting a market size of 500 million CNY[57]. - Market expansion efforts include entering two new provinces, aiming for a 5% market share increase in those regions[61]. Environmental Responsibility - The company is classified as a key pollutant discharge unit, with various pollutants monitored, including pH, suspended solids, and CODcr, all within regulatory limits[55]. - The company has implemented a comprehensive environmental self-monitoring plan, ensuring ongoing compliance with national regulations and standards[73]. - The company has been recognized as a provincial-level integrity enterprise for environmental credit evaluation for the year 2020, reflecting its commitment to environmental compliance[74]. - The company’s wastewater discharge from its facilities is treated to meet Class A standards before being released into the environment[67]. Corporate Governance - All directors attended the board meeting to review the report, ensuring accountability for the accuracy and completeness of the financial statements[1]. - The company plans not to distribute cash dividends or issue bonus shares for the reporting period[1]. - The company held its annual general meeting with a participation rate of 65.55% on May 20, 2022, and a temporary shareholders' meeting with a participation rate of 65.39% on July 18, 2022[49]. - The company has not engaged in any major litigation or arbitration matters during the reporting period[89]. Social Responsibility - The total value of the company's donations and contributions to social welfare exceeded 6.57 million yuan, including 2.76 million yuan worth of free medical assistance through the "Langshijie Muguangming" fund[84]. - The company established 10 medicinal herb planting bases and seedling centers across six provinces, providing employment for over 500 local farmers and increasing their income by more than 1 million yuan[86]. - The company plans to continue implementing the "Healthy China Strategy" and expand its public welfare projects, focusing on patient assistance and healthcare innovation[87]. Financial Management - The company has invested a total of 398,930,000 CNY in entrusted financial management products, with 124,850,000 CNY remaining unexpired[96]. - The company has multiple bank financial products with varying returns, including a floating return of 3.50% on a 15,000,000 CNY investment from Chengdu Bank[100]. - The company maintains a diversified portfolio of financial products to manage risk and optimize returns[96]. - The company reported a floating income of 3.28% from structured deposit products, indicating strong performance in financial services[103]. Operational Efficiency - The company is implementing new strategies to improve operational efficiency, targeting a 15% reduction in production costs by the end of 2022[57]. - The company has optimized equipment selection and strengthened cost control to ensure effective use of raised funds[41]. - The company has implemented cost-control measures that are projected to reduce operational expenses by 5% in the upcoming quarters[58]. Shareholder Information - The company reported a total share count of 919,463,954, with no new shares issued during the reporting period[113]. - The total number of common shareholders at the end of the reporting period is 56,551[115]. - The company has 228,805,885 restricted shares, accounting for 24.88% of total shares, with no changes in the number of restricted shares[112].

Financial Performance - The company's operating revenue for 2021 was ¥3,605,346,552.73, representing a year-over-year increase of 9.40% from ¥3,295,430,120.05 in 2020[11]. - The net profit attributable to shareholders for 2021 was ¥421,084,380.33, a significant increase of 256.04% compared to a loss of ¥269,853,091.45 in 2020[11]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥300,611,831.54, up 191.55% from a loss of ¥328,341,538.36 in 2020[11]. - The net cash flow from operating activities for 2021 was ¥494,114,176.33, an increase of 80.79% from ¥273,315,485.36 in 2020[11]. - The basic earnings per share for 2021 was ¥0.46, compared to a loss of ¥0.31 in 2020, marking a 248.39% improvement[11]. - Total revenue for 2021 reached ¥3,605,346,552.73, representing a year-on-year increase of 9.40% from ¥3,295,430,120.05 in 2020[29]. - The company achieved a net profit of CNY 300 million in 2021, which is a 15% increase compared to the previous year[89]. - Chengdu Kanghong Pharmaceutical Group reported a revenue increase of 20% year-over-year, reaching 1.5 billion RMB in 2021[169]. Dividend Distribution - The company plans to distribute a cash dividend of 1.00 RMB per 10 shares to all shareholders, based on a total of 919,463,954 shares[2]. - The cash dividend distribution was executed on June 11, 2021, following the approval of the shareholders' meeting[104]. - The company distributed a cash dividend of 1.00 RMB per 10 shares, totaling 91,946,395.40 RMB, which accounted for 100% of the total profit distribution[104][105]. Research and Development - The company focuses on the research, development, manufacturing, and sales of pharmaceutical products and medical devices, maintaining a commitment to innovation and collaboration[20]. - The company continues to enhance its R&D capabilities, transitioning from traditional Chinese medicine to innovative biopharmaceuticals[23]. - The company has launched 18 drugs, of which 12 are exclusive products, 13 are included in the national medical insurance catalog, and 7 are in the national essential drug list, establishing itself as a representative innovative pharmaceutical enterprise in China[24]. - The company has several ongoing R&D projects, including KH110-R01 for mild to moderate Alzheimer's disease, currently in Phase IIa and IIb, aimed at providing innovative treatment solutions[40]. - The company is preparing to apply for clinical research for KH631-R01, a gene therapy for wet age-related macular degeneration, with promising data indicating good drug development potential[42]. - The company is investing CNY 200 million in R&D for new drug development, focusing on innovative therapies for chronic diseases[89]. Market Position and Strategy - The company has strategically positioned itself in high-incidence diseases such as hypertension and diabetes, with a unique product layout in these areas[23]. - The company aims to improve public health by addressing the rising prevalence of age-related and chronic diseases due to an aging population[23]. - The company is exploring market expansion opportunities in Southeast Asia, targeting a 15% increase in international sales by 2023[88]. - The company plans to expand its market presence in Southeast Asia, targeting a 25% market share by 2025[172]. - The company is focused on market expansion and enhancing its product offerings in the pharmaceutical sector[187]. Corporate Governance - The company maintains complete independence from its controlling shareholder in business, personnel, assets, organization, and finance[73]. - The company has a robust internal governance structure, complying with relevant laws and regulations[72]. - The company has established a complete independent operational system, including procurement and sales[73]. - The company has a well-defined organizational structure with independent operation of the board and supervisory committees[73]. - The company has implemented a performance evaluation system linking remuneration to company performance and individual performance[90]. Environmental Compliance - The company has maintained compliance with environmental discharge standards across multiple pollutants[120]. - The company reported a pH discharge concentration of 6.87, within the acceptable range of 6-9[118]. - The company has implemented measures to ensure that all emissions are compliant with environmental regulations, demonstrating a commitment to sustainability[129]. - The company has engaged qualified third-party units for monitoring wastewater, waste gas, and noise, with all monitoring results meeting standards[143][144]. - The company has established emergency response plans for environmental incidents, with good operational status reported for all plans as of the latest updates[142]. Social Responsibility - The company actively participated in public health initiatives, including online health lectures and consultations, to promote the "Healthy China" strategy[149]. - The total value of donations and materials contributed to social welfare exceeded 71.85 million yuan, covering more than 30 provinces[149]. - The company received the "Five-Star" rating for its 2021 Social Responsibility Report, evaluated by the Chinese Academy of Social Sciences[146]. - The company was awarded the "AAA-level" credit rating in the national pharmaceutical industry and recognized as one of the top 100 pharmaceutical manufacturers in China[148]. - The company has established a series of public welfare projects focusing on rural revitalization and patient assistance, contributing to social welfare and healthcare improvement[149]. Future Outlook - Future outlook indicates a projected revenue growth of 20% for the next fiscal year, driven by new product launches and market expansion strategies[81]. - The company has set a performance guidance for 2022, targeting a revenue growth of 20% and a net profit growth of 25%[175]. - The company plans to launch three new products in the oncology segment by the end of 2022, aiming to capture a 10% market share in this sector[88]. - The company is exploring potential acquisitions in the biopharmaceutical sector to accelerate growth and innovation[172]. - The company is committed to maintaining a sustainable growth trajectory while ensuring compliance with regulatory standards in the pharmaceutical industry[176].

成都康弘药业集团股份有限公司 2022 年第一季度报告全文 证券代码：002773 证券简称：康弘药业 公告编号：2022-024 成都康弘药业集团股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准 确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带 的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明： 保证季度报告中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | |-----------------------------------------------------|------------------|------------------|---------------------------| | □ 是 √ 否 | ...